Spironolactone and hydrochlorothiazide

Spironolactone and hydrochlorothiazide is filed as Thiazide Diuretic [EPC]. The sections below restate public label fields stored for this profile.

Class
Thiazide Diuretic [EPC]
Route
ORAL
Dosage forms
HOW SUPPLIED Spironolactone and Hydrochlorothiazide Tablets, USP are available containing 25 mg of spironolactone, USP and 25 mg of hydrochlorothiazide, USP. The 25 mg/25 mg tablets are ivory, round, unscored tablets debossed with M over 41 on one side of the tablet and blank on the other side. They are available as follows: NDC 0378-0403-01 bottles of 100 tablets NDC 0378-0403-05 bottles of 500 tablets Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.] Protect from light. Dispense in a tight, light-resistant container as defined in the USP using a child-resistant closure. Distributed by: Mylan Pharmaceuticals Inc., a Viatris Company Morgantown, WV 26505 U.S.A. Revised: 3/2026 ALP:SPHZ:R5
Generic available
Yes
Manufacturer
Mylan Pharmaceuticals Inc.

Approved uses

Spironolactone, an ingredient of spironolactone and hydrochlorothiazide tablets, has been shown to be a tumorigen in chronic toxicity studies in rats (see Precautions section). Spironolactone and hydrochlorothiazide tablets should be used only in those conditions described below. Unnecessary use of this drug should be avoided. Spironolactone and hydrochlorothiazide tablets are indicated for: Edematous conditions for patients with:

How it works

Mechanism of action: Spironolactone and hydrochlorothiazide tablets are a combination of two diuretic agents with different but complementary mechanisms and sites of action, thereby providing additive diuretic and antihypertensive effects. Additionally, the spironolactone component helps to minimize the potassium loss characteristically induced by the thiazide component. The diuretic effect of spironolactone is mediated through its action as a specific pharmacologic antagonist of aldosterone, primarily by competitive binding of receptors at the aldosterone-dependent sodium-potassium exchange site in the distal convoluted renal tubule. Hydrochlorothiazide promotes the excretion of sodium and water primarily by inhibiting their reabsorption in the cortical diluting segment of the distal renal tubule. Spironolactone and hydrochlorothiazide tablets are effective in significantly lowering the systolic and diastolic blood pressure in many patients with essential hypertension, even when aldosterone secretion is within normal limits. Both spironolactone and hydrochlorothiazide reduce exchangeable sodium, plasma volume, body weight, and blood pressure. The diuretic and antihypertensive effects of the individual components are potentiated when spironolactone and hydrochlorothiazide are given concurrently.

Warnings and precautions

Potassium supplementation, either in the form of medication or as a diet rich in potassium, should not ordinarily be given in association with spironolactone and hydrochlorothiazide tablets therapy. Excessive potassium intake may cause hyperkalemia in patients receiving spironolactone and hydrochlorothiazide tablets (see Precautions : General ). Concomitant administration of spironolactone and hydrochlorothiazide tablets with the following drugs or potassium sources may lead to severe hyperkalemia: other potassium-sparing diuretics ACE inhibitors angiotensin II receptor antagonists aldosterone blockers non-steroidal anti-inflammatory drugs (NSAIDs), e.g., indomethacin heparin and low molecular weight heparin other drugs or conditions known to cause hyperkalemia potassium supplements diet rich in potassium salt substitutes containing potassium Spironolactone and hydrochlorothiazide tablets should not be administered concurrently with other potassium-sparing diuretics. Spironolactone, when used with ACE inhibitors or indomethacin, even in the presence of a diuretic, has been associated with severe hyperkalemia. Extreme caution should be exercised when spironolactone and hydrochlorothiazide tablets are given concomitantly with these drugs (see Precautions: Drug interactions ). Spironolactone and hydrochlorothiazide tablets should be used with caution in patients with impaired hepatic function because minor alterations of fluid and electrolyte balance may precipitate hepatic coma. Lithium generally should not be given with diuretics (see Precautions: Drug interactions ). Thiazides should be used with caution in severe renal disease. In patients with renal disease, thiazides may precipitate azotemia. Cumulative effects of the drug may develop in patients with impaired renal function. Thiazides may add to or potentiate the action of other antihypertensive drugs. Sensitivity reactions to thiazides may occur in patients with or without a history of allergy or bronchial asthma. Sulfonamide derivatives, including thiazides, have been reported to exacerbate or activate systemic lupus erythematosus.

Contraindications

Spironolactone and hydrochlorothiazide tablets are contraindicated in patients with anuria, acute renal insufficiency, significant impairment of renal excretory function, hypercalcemia, hyperkalemia, Addison's disease, and in patients who are allergic to thiazide diuretics or to other sulfonamide-derived drugs. Spironolactone and hydrochlorothiazide tablets may also be contraindicated in acute or severe hepatic failure.

Adverse reactions

The following adverse reactions have been reported and, within each category (body system), are listed in order of decreasing severity.

Dosage and administration

Optimal dosage should be established by individual titration of the components.

Drug interactions

ACE inhibitors, Angiotensin II receptor antagonists, aldosterone blockers, potassium supplements, heparin, low molecular weight heparin, and other drugs known to cause hyperkalemia: Concomitant administration may lead to severe hyperkalemia.

Common questions

What is Spironolactone and hydrochlorothiazide approved to treat?

According to its FDA label, Spironolactone and hydrochlorothiazide is approved for: Spironolactone, an ingredient of spironolactone and hydrochlorothiazide tablets, has been shown to be a tumorigen in chronic toxicity studies in rats (see Precautions section). Spironolactone and hydrochlorothiazide tablets should be used only in those conditions described below.… For medical advice, please talk to your prescriber or pharmacist.

What class of drug is Spironolactone and hydrochlorothiazide?

Spironolactone and hydrochlorothiazide belongs to the Thiazide Diuretic [EPC] class of medications.

What form does Spironolactone and hydrochlorothiazide come in?

The FDA label lists Spironolactone and hydrochlorothiazide as: HOW SUPPLIED Spironolactone and Hydrochlorothiazide Tablets, USP are available containing 25 mg of spironolactone, USP and 25 mg of hydrochlorothiazide, USP. The 25 mg/25 mg tablets are ivory, round, unscored tablets debossed with M over 41 on one side of the tablet and blank on the other side. They are available as follows: NDC 0378-0403-01 bottles of 100 tablets NDC 0378-0403-05 bottles of 500 tablets Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.] Protect from light. Dispense in a tight, light-resistant container as defined in the USP using a child-resistant closure. Distributed by: Mylan Pharmaceuticals Inc., a Viatris Company Morgantown, WV 26505 U.S.A. Revised: 3/2026 ALP:SPHZ:R5; oral route. Available strengths and packaging vary by manufacturer.

Is there a generic version of Spironolactone and hydrochlorothiazide?

Yes. A generic version of Spironolactone and hydrochlorothiazide is available in the U.S. Ask your pharmacist about substitution.

Does Spironolactone and hydrochlorothiazide have a Boxed Warning?

Our ingest of the FDA label for Spironolactone and hydrochlorothiazide does not include a Boxed Warning at this time. See the full label on DailyMed for the current, authoritative version.

Is Spironolactone and hydrochlorothiazide currently under recall?

The FDA Enforcement Report does not show an active/ongoing recall for Spironolactone and hydrochlorothiazide in our latest ingest. Recall data can change daily — verify at FDA.gov.

When was Spironolactone and hydrochlorothiazide approved by the FDA?

The FDA record lists the approval date for Spironolactone and hydrochlorothiazide as 1979-08-03.

Who makes Spironolactone and hydrochlorothiazide?

The FDA label lists Mylan Pharmaceuticals Inc. as a labeler/manufacturer of Spironolactone and hydrochlorothiazide. Multiple firms may market generics of the same molecule.

How should Spironolactone and hydrochlorothiazide be stored?

The FDA label states: "Spironolactone and hydrochlorothiazide tablets, USP are supplied as follows: Spironolactone and hydrochlorothiazide tablets, 25 mg/25 mg are buff, round, unscored, debossed MP 40. NDC: 72162-1625-0: 1000 Tablets in a BOT…" Follow the packaging insert for the authoritative guidance.

On this site

Related medications in this class or category

Loading full data from Know Your Drugs Institute…